# Gradient Fractionated Separation of Chondrogenically Committed Cells Derived from Human Embryonic Stem Cells

**Authors:** Natasja Leth Joergensen, Anette Gabrielsen, Martin Lind, Helle Lysdahl

PMC · DOI: 10.1089/biores.2014.0051 · BioResearch Open Access · 2015-01-01

## TL;DR

This paper describes a method to separate chondrogenically committed cells from human embryonic stem cells using a density gradient, improving cell homogeneity for cartilage regeneration.

## Contribution

A new strategy using micromass culture and density gradient separation to obtain more homogeneous chondrogenic cell populations from hESCs.

## Key findings

- Chondrogenic conditions significantly affected gene expression levels of NANOG, OCT4, SOX5, SOX9, ACAN, and COL2A1 in all fractions.
- Fraction F4 showed higher expression of NANOG, OCT4, and SOX9 compared to F3, while COL2A1 and COL2A1:COL1A1 ratio were lower.
- F3 cells were more morphologically homogeneous than F4 cells based on toluidine blue staining.

## Abstract

Cartilage regeneration is a fast growing field that combines biotechnology and molecular techniques in creating new tissue mimicking the native microenvironment. Human embryonic stem cells (hESCs) are a highly potent cell source for cartilage regeneration owing to their infinite proliferation capacity and pluripotency. Thus, lineage-specific differentiation of hESCs often results in populations with cellular heterogeneity. Chondrogenesis was induced through high-density micromass culture of hESCs and by addition of chondrogenic medium; 1:100 ITS+, 100 nM dexamethasone, 40 μg/ml l-proline, 50 μg/mL ascorbic acid-2-phosphate, 1:100 Knockout serum, and 10 ng/mL TGFβ3. At day 14 micromasses were dissociated and chondrogenically committed cell separated in a fraction-based discontinuous density gradient. After fractionation the chondrogenically committed cells were analyzed with regard to embryonic- and chondrogenic gene expression and fraction F3 and F4 with histology. In general, we found that the chondrogenic condition compared with the control condition had a significant effect on the following gene expression levels: NANOG, OCT4, SOX5, SOX9, ACAN, and COL2A1 in all fractions. Furthermore, we found in the chondrogenic condition that NANOG, OCT4, and SOX9 were significantly higher in F4 compared with F3, whereas COL2A1 and the ratio COL2A1:COL1A1 were significantly lower. Additionally, toluidine blue pH 4 stains of pellet cultures of F3 and F4 revealed that cells from F3 were more homogenous in morphology than F4. In conclusion, we propose a simple strategy to obtain more homogenous population of chondrogenically committed cells from hESCs using micromass culture and discontinuous density gradient separation.

## Linked entities

- **Genes:** NANOG (Nanog homeobox) [NCBI Gene 79923], POU5F1 (POU class 5 homeobox 1) [NCBI Gene 5460], SOX5 (SRY-box transcription factor 5) [NCBI Gene 6660], SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662], ACAN (aggrecan) [NCBI Gene 176], COL2A1 (collagen type II alpha 1 chain) [NCBI Gene 1280], COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277]
- **Chemicals:** dexamethasone (PubChem CID 5743), l-proline (PubChem CID 145742), ascorbic acid-2-phosphate (PubChem CID 54679073)

## Full-text entities

- **Genes:** COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, POU5F1 (POU class 5 homeobox 1) [NCBI Gene 5460] {aka OCT3, OCT4, OCT4Borf1, OTF-3, OTF3, OTF4}, SOX6 (SRY-box transcription factor 6) [NCBI Gene 55553] {aka HSSOX6, SOXD, TOLCAS}, SOX5 (SRY-box transcription factor 5) [NCBI Gene 6660] {aka L-SOX5, L-SOX5B, L-SOX5F, LAMSHF}, RPL15 (ribosomal protein L15) [NCBI Gene 6138] {aka DBA12, EC45, L15, RPL10, RPLY10, RPYL10}, COL2A1 (collagen type II alpha 1 chain) [NCBI Gene 1280] {aka ACG2, ANFH, ANFH1, AOM, COL11A3, EDMMD}, SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662] {aka CMD1, CMPD1, ENH13, SRA1, SRXX2, SRXY10}, NANOG (Nanog homeobox) [NCBI Gene 79923], TGFB3 (transforming growth factor beta 3) [NCBI Gene 7043] {aka ARVD, ARVD1, LDS5, RNHF, TGF-beta3}, CDC14A (cell division cycle 14A) [NCBI Gene 8556] {aka DFNB105, DFNB32, DFNB35, cdc14, hCDC14}, DNASE1 (deoxyribonuclease 1) [NCBI Gene 1773] {aka DNL1, DRNI}, ACAN (aggrecan) [NCBI Gene 176] {aka AGC1, AGCAN, CSPG1, CSPGCP, MSK16, SEDK}
- **Diseases:** teratoma (MESH:D013724)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** hESCs — Homo sapiens (Human), Embryonic stem cell (CVCL_UI95), CLS1 — Homo sapiens (Human), Rhabdoid tumor of the kidney, Cancer cell line (CVCL_5904)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4497648/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4497648/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC4497648/full.md

---
Source: https://tomesphere.com/paper/PMC4497648